How will attending this event will benefit you?
ENDS is Europe’s leading ENDS conference to look at scientific, commercial and regulatory aspects; covering everything from the latest regulations (including TPD3) and the latest research to testing methods, concerns and standards, products design, potential harm reduction and much more.
Previous delegates attended from testing companies, Big Tobacco, ENDS/ELiquid manufacturers, ingredients manufactures, regulatory and legislatory bodies, law firms and more were in attendance. So this conference was truly a must attend for the industry. Just some of the attendee's included representatives from British American Tobacco, Philip Morris International, Japan Tobacco International, Nicopure Labs, CORESTA, FDA MHRA, UKVIA, Totally Wicked, INNCO, Imperial Brands, IBVTA and more.
If you missed the event, you can still catch-up with all the sessions and presentations by purchasing an on-demand access pass. For just €499, you'll be able to watch back all of the presentations and connect with the delegates via the online event platform.
 |
 |
Christopher Snowdon is the Head of Lifestyle Economics at the IEA. He is the author of The Art of Suppression, The Spirit Level Delusion and Velvet Glove; Iron Fist. His work focuses on pleasure, prohibition and dodgy statistics. He has authored a number of publications including Sock Puppets, Euro Puppets, The Proof of the Pudding, The Crack Cocaine of Gambling and Free Market Solutions in Health.
Nick is a Principal Scientist at Hall Analytical Laboratories responsible for providing technical support to new and existing pharma, med device and ENDs customers in the field of extractables and leachables. Nick’s area of expertise includes E&L study design, defining E&L strategies, performing leachable risk assessments and authoring E&L regulatory sections.
Prior to joining Hall, Nick spent over 10 years at GSK in the field of extractables and leachables. During this time, he worked on a range of therapeutic areas including inhalation, topical and parenteral. Where he had responsibility for the E&L assessment of devices, closure systems and manufacturing processes to ensure patient safety, product quality and regulatory approval.
A former governmental official and researcher, Dr Foltea is a lawyer advising global companies and governmental institutions around the world. Her main areas of expertise are international economic agreements and organisations, notably the WTO, FTAs and International Investment Agreements (IIAs). She specializes in the WTO accessions, market access, trade policy reviews, dispute settlement.
Since September 2016 she is on the Indicative List of WTO Panels, which makes her eligible to solve WTO disputes. Starting 2019, Dr Foltea is one of the five experts sitting on the WTO Permanent Group of Experts on Subsidies and Countervailing Measures. She is a frequent speaker in international events and has spoken in the European Parliament.
Dr Foltea has obtained her Ph.D. in International Economic Law in 2010 from the University of Bern winning the Walther Hug prize for the best legal dissertation in Switzerland. She is also Assistant Professor at the Polish Academy of Sciences (Institute of Law Studies) focusing on legal aspects in the control of illicit trade in the EU.
Marina Foltea is Founder and Managing Director of Trade Pacts, Geneva.
Dustin Dahlmann from Hamburg, Germany is the president of the Independent European Vape Alliance (IEVA), the German vaping industry association BfTG (Bündnis für Tabakfreien Genuss e.V.) and owner of the successful e-cigarette wholesale InnoCigs. He fights for an autonomous regulation of vaping products as a means to harm reduction independent from tobacco industries throughout Europe.
Rob de Lange chairs Acvoda, the Dutch non-profit organisation which supports Harm Reduction alternatives for consumers, since 2018. Acvoda strives to inform consumers on the risks and benefits of Harm Reduction alternatives to smoking, based on unbiased , peer reviewed studies and scientific research. Mr. de Lange holds the view that only truth based factual information can withstand scrutiny and form a formidable defence against inappropriate regulations and non Harm Reduction based Tobacco regulating ideologies.
As Acvoda’s chair, he holds meetings with consumers, scientists, researchers and policy-makers and acts as a liaison for the Dutch e-cigarette trade organisation, as well as writing various media articles on Harm Reduction. With various certifications in IT-security, Mr. de Lange is well equipped to discern facts from fiction.
Rob de Lange was appointed president of INNCO in 2021.
I developed a vaping machine named U-SAV in 2015-2016. I am an expert on AFNOR, CEN and ISO committees on vaping products since 2016 and I am in charge of two documents. I defended with success a PhD in January 2021 titled "Thermodynamics contribution to the understanding of the electronic cigarette functioning". I also published papers on the functioning of vaping devices [ORCID: 0000-0002-7802-7233].
-(002)-png-(email-signature)-644x250.png?ext=.png){kind=logo}
Broughton is an independent life sciences contract research organization serving a global roster of clients from Europe, North America, the Middle East, Asia, and Australia. We offer high quality drug and device development services across all stages of the pharmaceutical, nicotine and cannabinoid product lifecycle. With over 15 years of scientific experience and a world-leading team of scientific and regulatory consultants we support our partners bringing innovative products to market to improve societal health and well-being. Our in-house laboratory testing facilities are GMP compliant and regularly inspected by the Medicines and Healthcare products Regulatory Agency (MHRA), U.S. Food and Drug Administration (FDA) and the United Kingdom Accreditation Service (UKAS). The foundation of the Broughton business is excellence in chemistry, the acceleration of innovative products to market and aligning our services with areas of unmet need within the life sciences industry.
Cambridge Design Partnership is an end-to-end innovation partner, propelling global brands and ambitious start-ups to success. We build breakthrough products and services – from insight to ideas, prototypes to production – bringing innovation to life. Our teams are multi-disciplinary, uniting scientific rigor, design ingenuity, and engineering excellence for consumer, healthcare, and industrial clients.
We develop innovative nicotine delivery systems that reduce risk, provide a satisfying user experience, and redefine expectations in a competitive market.
Our world-class team have been advancing commercially successful tobacco harm reduction products since the category emerged. We have established sophisticated nicotine-yielding product testing facilities and deep knowledge of aerosol generation, underpinned by our work on medical devices. Our experience supports clients in their product stewardship: selecting materials, testing for safety, quality, user experience, and navigating the regulatory landscape.
The result: commercial success for our clients, a positive impact on public health, and millions of lives improved through innovation.
DCA is a leading product design and development consultancy. We combine our skills and experience to help to deliver strategically important and technically demanding projects.
We work closely with your teams, understanding your place in the market and your ambitions, ultimately delivering commercially successful innovative products together.
Hall Analytical (part of Element Materials Technology) is an ISO 17025:2017, GLP accredited testing laboratory, with over 10 years’ experience in the analysis of nicotine-containing Reduced-Risk Products (RRPs). Our custom-designed laboratories have dedicated wet lab facilities for RRP sample preparation, with separate fully equipped ENDS & HTPs aerosol collection labs, operated by our highly trained technical staff. We support the needs of our customers by providing high-quality data for regulatory submission (FDA PMTA, EU TPD2) and new RRP development, enabling them to deliver the next generation of harm reduction products to worldwide nicotine consumers.
